Strategic Acquisition Icelandirect recently expanded its capabilities by acquiring SOMA LABS, enhancing solid dosage form production. This presents a cross-sell opportunity to its existing customers seeking integrated manufacturing and wider product formats, as well as a pathway to enter new distributors with broader catalog coverage.

Quality and Compliance The company highlights GMP compliance, FDA guidelines adherence, and SSCI certification. Use these certifications to position Icelandirect as a trusted contract manufacturer for risk-averse brands seeking reliable compliance, enabling premium formulations and private-label partnerships.

Turnkey Solutions With turnkey services including custom formulation, packaging design, labeling, warehousing and fulfillment, Icelandirect can be pitched as a one-stop partner for brands looking to outsource end-to-end operations, accelerating go-to-market timelines for new products.

pet and human markets Icelandirect serves both human and pet nutraceuticals, with human-grade omega products for pets (HGO3). This dual-market capability enables cross-market upsell opportunities to existing pet brands and to human-focused supplement manufacturers seeking to expand pet product lines.

Expanding reach Recent SSCI certification and national distribution channels, plus robust e-commerce presence via Amazon and others, indicate growing market credibility. Leverage these signals to approach retailers, e-commerce platforms, and private-label buyers seeking compliant, high-quality omega and vegan options at scale.